
Zimmer Biomet Achieves 7.2% Sales Growth Amid Strategic Tech Acquisitions
Zimmer Biomet Holdings, Inc.Description
What this story covers
Zimmer Biomet’s 2025 10-K reveals 7.2% sales growth driven by the Paragon 28 acquisition and ZBEdge robotic integration. Despite a dip in net earnings due to restructuring and inventory charges, strong cash flows support a positive 2026 outlook.
Story snapshot
CompanyZimmer Biomet Holdings, Inc.
TickerZBH
VariantStandard detailed
Duration10:47
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0001193125-26-059853
Sources1
Full Story Script
Content not available for this story.